Page 24 - RPIA_25-2

Frederico Regateiro, Ana Luísa Moura, Emília Faria

8. Flood -Page P, Menzies -Gow A, Phipps S, Ying S, Wangoo A, noclonal antibody, versus placebo for uncontrolled eosinophilic
Ludwig MS, et al. Anti -IL -5 treatment reduces deposition of asthma: A phase 2b randomised dose -ranging study. Lancet Res-
ECM proteins in the bronchial subepithelial basement mem- pir Med 2014;2(11):878-90.
brane of mild atopic asthmatics. J Clin Invest 2003;112(7):1029- 21. Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF,
-36. Barker P, et al. Efficacy and safety of benralizumab for patients
9. Flood -Page P, Swenson C, Faiferman I, Matthews J, Williams M, with severe asthma uncontrolled with high -dosage inhaled cor-
Brannick L, et al. A study to evaluate safety and efficacy of me- ticosteroids and long -acting β2 -agonists (SIROCCO): a randomi-
polizumab in patients with moderate persistent asthma. Am J sed, multicentre, placebo -controlled phase 3 trial. Lancet 2016;
Respir Crit Care Med 2007;176(11):1062-71. 388(10056):2115-27.
10. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, 22. FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommat-
et al. Mepolizumab for severe eosinophilic asthma (DREAM): A zsch M, et al. Benralizumab, an anti -interleukin -5 receptor α
multicentre, double -blind, placebo -controlled trial. Lancet monoclonal antibody, as add -on treatment for patients with
2012;380(9842):651-9. severe, uncontrolled, eosinophilic asthma (CALIMA): a randomi-
11. Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, sed, double -blind, placebo -controlled phase 3 trial. Lancet 2016;
Chetta A, et al. Mepolizumab Treatment in Patients with Severe 388(10056):2128-41.
Eosinophilic Asthma. N Engl J Med 2014;371(13):1198-207. 23. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Ya-
12. Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleec- ncopoulos GD. Targeting key proximal drivers of type 2 inflamma-
ker ER, et al. Severe eosinophilic asthma treated with mepolizu- tion in disease. Nat Rev Drug Discov 2016;15(1):35-50.
mab stratified by baseline eosinophil thresholds: a secondary 24. Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer
analysis of the DREAM and MENSA studies. Lancet Respir SK, et al. Lebrikizumab in moderate -to -severe asthma: pooled
2016;2600(16):1-8. data from two randomised placebo -controlled studies. Thorax
13. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yan- 2015;70:748-56.
cey SW, et al. Oral glucocorticoid -sparing effect of mepolizumab 25. Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky
in eosinophilic asthma. N Engl J Med 2014;371(13):1189-97. P, Paggiaro P, et al. Efficacy and safety of lebrikizumab in patients
14. Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, with uncontrolled asthma (LAVOLTA I and LAVOLTA II): repli-
et al. Long -term efficacy and safety of mepolizumab in patients cate, phase 3, randomised, double -blind, placebo -controlled trials.
with severe eosinophilic asthma: A multi -center, open -label, pha- Lancet Respir Med 2016;4(10):781-96.
se IIIb study. Clin Ther 2016;38(9):2058-70.e1. 26. Brightling CE, Chanez P, Leigh R, O Byrne PM, Korn S, She D, et
15. Kim S, Marigowda G, Oren E, Israel E, Wechsler ME. Mepolizumab al. Efficacy and safety of tralokinumab in patients with severe
as a steroid -sparing treatment option in patients with Churg- uncontrolled asthma: A randomised, double -blind, placebo-
-Strauss syndrome. J Allergy Clin Immunol 2010;125(6):1336-43. -controlled, phase 2b trial. Lancet Respir Med 2015;3(9):692-701.
16. Moosig F, Gross WL, Herrmann K, Bremer JP, Hellmich B. Tar- 27. Takayama G, Arima K, Kanaji T, Toda S, Tanaka H, Shoji S, et al.
geting interleukin -5 in refractory and relapsing Churg -Strauss Periostin: A novel component of subepithelial fibrosis of bronchial
syndrome. Ann Intern Med 2011;155(5):341. asthma downstream of IL -4 and IL -13 signals. J Allergy Clin Immu-
17. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, nol 2006;118(1):98-104.
Bardin P, et al. Reslizumab for inadequately controlled asthma 28. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et
with elevated blood eosinophil counts: Results from two multi- al. Dupilumab efficacy and safety in adults with uncontrolled per-
centre, parallel, double -blind, randomised, placebo -controlled, sistent asthma despite use of medium -to -high -dose inhaled cor-
phase 3 trials. Lancet Respir Med 2015;3(5):355-66. ticosteroids plus a long -acting β 2 agonist: a randomised double-
18. Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Dams- -blind placebo -controlled pivotal phase 2b dose -ranging trial.
chroder MM, et al. MEDI -563, a humanized anti -IL -5 receptor α Lancet 2016;6736(16):1.
mAb with enhanced antibody -dependent cell -mediated cyto- 29. Boyman O, Kaegi C, Akdis M, Bavbek S, Bossios A, Chatzipetrou
toxicity function. J Allergy Clin Immunol 2010;125(6):1344-53. A, et al. EAACI IG Biologicals task force paper on the use of
e2. biologic agents in allergic disorders. Vol. 70, Allergy: European
19. Pham TH, Damera G, Newbold P, Ranade K. Reductions in eo- Journal of Allergy and Clinical Immunology 2015;727-54.
sinophil biomarkers by benralizumab in patients with asthma. 30. Liu Y -J, Soumelis V, Watanabe N, Ito T, Wang Y -H, Malefyt RDW,
Respir Med 2016;111:21-9. et al. TSLP: an epithelial cell cytokine that regulates T cell diffe-
20. Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse rentiation by conditioning dendritic cell maturation. Annu Rev
WW, et al. Benralizumab, an anti -interleukin 5 receptor α mo- Immunol 2007;25(1):193-219.

112

REVIST A POR TUGUESA DE IMUNO ALERGOLOGIA